Pfizer’s under development SARS-CoV-2 protease inhibitor antiviral therapy for oral use has the potential of reducing hospitalisation or death by as much as 89% in COVID-19 patients, the company claimed in a statement on November 5, 2021.
The primary interim data came after evaluating 1219 patients, the statement issued by the company read.
Pfizer said that the trial is being conducted across Europe, Africa, North and South America and Asia, in multiple centres with 45% of patients located in the United States.
Albert Bourla, Chairman and Chief Executive Officer, Pfizer said, “Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate if approved or authorised by regulatory authorities has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalisations.”
“Given the continued global impact of COVID-19, we have remained laser-focused on the science and fulfilling our responsibility to help healthcare systems and institutions around the world while ensuring equitable and broad access to people everywhere,” he added.
If authorised for use for treating COVID-19 patients, the company plans to initiate ‘tiered pricing approach' based on the income level in order to ‘promote equity of access across the globe, the company informed.